AI and machine learning are becoming increasingly important in antibody discovery, but the field is moving beyond the idea that computational tools will simply replace experimental science. The most valuable progress is happening where AI is integrated with high-throughput screening, structured experimental datasets and rigorous wet-lab validation.
In the full article, Isogenica explores where AI is already adding value — from candidate ranking and structure-assisted triage to affinity maturation, stability engineering, liability reduction and literature mining. These tools can help scientists prioritise candidates earlier and focus experimental effort where it is most likely to matter.
The blog also looks at the limitations. Predicting therapeutic-grade antibodies remains difficult because successful candidates must satisfy many interconnected criteria, including affinity, specificity, manufacturability, immunogenicity, stability, aggregation risk and in vivo performance.
A key theme is data quality. Machine learning performs best when trained on large, standardised and reproducible datasets. Synthetic antibody libraries and fully in vitro workflows may therefore have an important role to play, generating cleaner experimental outputs and faster test-learn cycles that better support AI-assisted discovery.
Read the full blog: https://isogenica.com/ai-in-antibody-discovery-ml-advances-limitations-and-future/